SILO Pharma (SILO Pharma) Forward Dividend Yield % : 0.00% (As of Jun. 08, 2024)

View and export this data going back to 2012. Start your Free Trial

What is SILO Pharma Forward Dividend Yield %?

As of today (2024-06-08), the Forward Annual Dividend Yield of SILO Pharma is 0.00%.

As of today (2024-06-08), the Trailing Annual Dividend Yield of SILO Pharma is 0.00%.

SILO's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.63
* Ranked among companies with meaningful Forward Dividend Yield % only.

SILO Pharma's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of SILO Pharma's Forward Dividend Yield %

For the Biotechnology subindustry, SILO Pharma's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SILO Pharma's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SILO Pharma's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where SILO Pharma's Forward Dividend Yield % falls into.

SILO Pharma Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

SILO Pharma (NAS:SILO) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

SILO Pharma Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of SILO Pharma's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

SILO Pharma (SILO Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SILO Pharma Inc (NAS:SILO) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

560 Sylvan Avenue, Suite 3160, Englewood Cliffs, NJ, USA, 07632

Website

https://www.silopharma.com

SILO Pharma Inc is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company is engaged in developing innovative solutions to address a variety of underserved conditions which includes Alzheimer's; Parkinson's; Multiple Sclerosis (MS); Rheumatoid Arthritis (RA); and Stress-Induced Psychiatric Disorders.

Executives

Eric Weisblum	director, officer: President and CCO	285 GRAND AVENUE, ENGLEWOOD NJ 07631
Daniel E. Ryweck	officer: Chief Financial Officer	712 VISTA BLVD #305, WACONIA MN 55387
Jeff Pavell	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Kevin Munoz	director	560 SYLVAN AVE, SUITE 3160, ENGLEWOOD CLIFF NJ 07632
Wayne Linsley	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Adam C Wasserman	officer: Chief Financial Officer	1643 ROYAL GROVE WAY, WESTON FL 33327
Leonard M Schiller	director
Joel Alan Stone,	director	1772 SABAL PALM DR., BOCA RATON FL 33432
Parker Walter Van Eps	director	C/O PROSPECT ENERGY CORPORATION, 10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Richard Brand	director, officer: Chairman and CEO	10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Whalehaven Capital Fund Ltd	10 percent owner	P O BOX HM 1027, HAMILTON D0 HMDX
Vadim Mats	officer: VP of Business Development	285 GRAND AVENUE, ENGLEWOOD NJ 07631
Donald Ptalis	director, officer: CFO	72 POND ROAD, WOODBURY NY 11797
Melvin Schlossberg	director, 10 percent owner, officer: PRESIDENT, CEO & SECRETARY	72 POND ROAD, WOODBURY NY 11797